BioRestorative Therapies (BRTX) Free Cash Flow (2010 - 2025)

BioRestorative Therapies (BRTX) has 16 years of Free Cash Flow data on file, last reported at -$2.5 million in Q4 2025.

• Quarterly Free Cash Flow fell 5.06% year-over-year to -$2.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$10.9 million (down 30.94% YoY) and the FY2025 annual result came in at -$10.9 million, down 30.94% from the prior year.
• Free Cash Flow advanced to -$2.5 million in Q4 2025, from -$2.9 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$629364.0 in Q3 2021 to a low of -$2.9 million in Q3 2025.
• A 5-year average of -$1.8 million and a median of -$1.7 million in 2022 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow sank 126.74% — and 2023, when it rose 16.52%.
• Tracing BRTX's Free Cash Flow over 5 years: stood at -$1.1 million in 2021, then slumped by 44.83% to -$1.7 million in 2022, then climbed by 0.02% to -$1.7 million in 2023, then tumbled by 42.36% to -$2.4 million in 2024, then fell by 5.06% to -$2.5 million in 2025.
• The last three Free Cash Flow figures came in at -$2.5 million (Q4 2025), -$2.9 million (Q3 2025), and -$2.7 million (Q2 2025), per Business Quant data.